GlassScriptPhysician profile
Caitlin E Mathison
NPI 1194152553
$6,251.01
in general payments reported to CMS, 2019-2025
42 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,174 · 2022: $1,282 · 2023: $966 · 2024: $1,458 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,733 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,732.87 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $899.31 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $521.61 | 2021-2025 | |
| Abbott Laboratories | $458.10 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.55 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $403.71 | 2021-2024 | Brilinta, Atacand, Farxiga |
| Amgen INC. | $290.29 | 2021-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $275.96 | 2021-2025 | Eliquis, Camzyos |
| Pfizer INC. | $259.31 | 2021-2025 | |
| Chiesi USA, INC. | $245.66 | 2021-2024 | Kengreal, Cleviprex |
| Merck Sharp & Dohme LLC | $242.91 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $176.16 | 2024-2025 | |
| Novo Nordisk INC | $162.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $157.81 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $148.22 | 2024-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $144.41 | 2021-2025 | Nexletol |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $129.62 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.42 | 2022-2024 | Lifevest |
| Edwards Lifesciences Corporation | $97.81 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $93.28 | 2021-2023 | Watchman, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $77.78 | 2021-2023 | |
| Baxter Healthcare | $77.73 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $74.83 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $68.98 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $63.44 | 2022-2023 | Arcalyst |
| Philips North America LLC | $62.48 | 2024 | (Ck4) Mcot |
| Abiomed | $55.19 | 2023-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $54.72 | 2024 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $46.02 | 2023-2024 | Optimizer, Optimizer |
| Cardiva Medical, INC. | $42.67 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $42.12 | 2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $40.76 | 2021-2022 | |
| Lilly USA, LLC | $38.04 | 2025 | Zepbound |
| Medtronic, INC. | $36.55 | 2022-2023 | Micra |
| Bardy Diagnostics, INC. | $34.05 | 2022 | |
| United Therapeutics Corporation | $29.60 | 2023 | Tyvaso |
| Kowa Pharmaceuticals America, INC. | $28.83 | 2021-2022 | |
| Medicomp INC | $18.34 | 2024 | Telepatch Cardiac Monitor |
| Glaxosmithkline, LLC. | $18.03 | 2025 | Shingrix |
| Cashflow Solutions, LLC | $16.03 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Amryt Pharma Holdings LTD | $15.73 | 2021 | |
| Lundbeck LLC | $12.11 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $10.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Mathison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.